References
- 1. Gostin L, Buckley G, Kelley P. Stemming the global trade in falsified and substandard medicines. JAMA. 2013;309:1693-1694.10.1001/jama.2013.304823579391
- 2. Hamilton WL, Doyle C, Halliwell-Ewen M, Lambert G. Public Health Interventions to Protect against Falsified Medicines: A Systematic Review of International, National and Local Policies. Health Policy Plan. 2016;31:1448–1466.10.1093/heapol/czw06227311827
- 3. Haleem RM, Salem MY, Fatahallah FA, Abdelfattah LE. Quality in the pharmaceutical industry - A literature review. Saudi Pharm J. 2015;23:463–469.10.1016/j.jsps.2013.11.004460591726594110
- 4. Cordon C, Garcia-Milà P, FerreiroVilarino T, Caballero P. Strategy is Digital: How Companies Can Use Big Data in the Value Chain. New York: Springer International Publishing; 2016, 47-64.10.1007/978-3-319-31132-6_3
- 5. Chiacchio F, Compagno L, D’Urso D, Velardita L, Sandner P. A Decentralised Application for the Traceability Process in the Pharma Industry. Procedia Manufacturing, International Conference on Industry 4.0 and Smart Manufacturing. 2020;42:362–369.
- 6. Trenfield SJ, Xian Tan H, Awad A, et al. Track-and-Trace: Novel Anti-Counterfeit Measures for 3D Printed Personalized Drug Products Using Smart Material Inks. International Journal of Pharmaceutics. 2019;567:e118443.10.1016/j.ijpharm.2019.06.03431212052
- 7. Bandyopadhyay S. The Internet And Gray Marketing. International Business & Economics Research Journal. 2010;9:95-102.10.19030/iber.v9i6.588
- 8. Brechtelsbauer ED, Pennell B, Durham M, Hertig JB, Weber RJ. Review of the 2015 Drug Supply Chain Security Act. Hosp Pharm. 2016;51:493–500.10.1310/hpj5106-493491199227354753
- 9. U.S. Food&Drug Administration. Counterfeit medicine. https://www.fda.gov/drugs/buying-using-medicine-safely/counterfeit-medicine
- 10. Center for Disease Control and Prevention. Counterfeit medicine. https://wwwnc.cdc.gov/travel/page/counterfeit-medicine
- 11. Interpol. Fake medicines. https://www.interpol.int/en/Crimes/Illicit-goods/Shop-safely/Fake-medicines
- 12. Williams L, McKnight E. The real impact of counterfeit medications. US Pharmacist. 2014;39:44-46.
- 13. Ozawa S, Evans DR, Bessias S, et al. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. JAMA Netw Open. 2018;1:e181662.10.1001/jamanetworkopen.2018.1662632428030646106
- 14. Kelesidis T, Falagas ME. Substandard/Counterfeit Antimicrobial Drugs. Clin Microbiol Rev. 2015;28:443-464.10.1128/CMR.00072-14440295825788516
- 15. Almuzaini T, Choonara I, Sammons H. Substandard and Counterfeit Medicines: A Systematic Review of the Literature. BMJ Open. 2013;3:e002923.10.1136/bmjopen-2013-002923375204923955188
- 16. Lee JH, Park HN, Kim NS, et al. Application of Screening Methods for Weight-Loss Compounds and Identification of New Impurities in Counterfeit Drugs. Forensic Sci Int. 2019;303:e109932.10.1016/j.forsciint.2019.10993231473560
- 17. Soares F, Anzanello MJ, Fogliatto FS, Ortiz RS, Mariotti KC, Ferrao MF. Enhancing counterfeit and illicit medicines grouping via feature selection and X-ray fluorescence spectrometry. J Pharm Biomed Anal. 2019;174:198-205.10.1016/j.jpba.2019.05.06431174131
- 18. Naughton B, Roberts L, Dopson S, Chapman S, Brindley D. Effectiveness of Medicines Authentication Technology to Detect Counterfeit, Recalled and Expired Medicines: A Two-Stage Quantitative Secondary Care Study. BMJ. 2016;12:e013837.10.1136/bmjopen-2016-013837516865527940634
- 19. Kovacs S, Hawes SE, Maley SN, Mosites E, Wong L, Stergachis A. Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries. PLoS One. 2014;9:e90601.10.1371/journal.pone.0090601396673824671033
- 20. Martino R, Malet-Martino M, Gilard V, Balayssac S. Counterfeit drugs: analytical techniques for their identification. Anal Bioanal Chem. 2010;398:77-92.10.1007/s00216-010-3748-y20437031
- 21. Bansal D, Malla S, Gudala K, Tiwari P. Anti-Counterfeit Technologies: A Pharmaceutical Industry Perspective. Sci Pharm. 2013;81:1-13.10.3797/scipharm.1202-03361766623641326
- 22. Mackey TK, Nayyar GA. Review of Existing and Emerging Digital Technologies to Combat the Global Trade in Fake Medicines. Expert Opin Drug Saf. 2017;16:587-602.10.1080/14740338.2017.131322728349715
- 23. Deus L. Technological Roles in Combating Drug Diversion and Counterfeiting. Journal of Pharmacy Practice. 2006;19:146-152.10.1177/0897190006292943
- 24. U.S. Food&Drug Administration. FDA In Brief: FDA advances policies related to bolstering security of drug products in the U.S. supply chain. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-advances-policies-related-bolstering-security-drug-products-us-supply-chain
- 25. Chiacchio F, D’Urso D, Compagno L, Chiarenza M, Velardita L. Towards a Blockchain Based Traceability Process: A Case Study from Pharma Industry, in Ameri F, Stecke KE, von Cieminski G, Kiritsis D (eds): Advances in Production Management Systems. Production Management for the Factory of the Future. Springer International Publishing, Cham Switzerland, 2019, 451–45710.1007/978-3-030-30000-5_56
- 26. Taylor D. RFID in the Pharmaceutical Industry: Addressing Counterfeits with Technology. J Med Syst. 2014;38(141):1-5.10.1007/s10916-014-0141-y25308613
- 27. Center for Disease Control and Prevention. The drug Supply Chain Security Act and 2D Vaccine Barcodes. https://www.cdc.gov/vaccines/programs/iis/2d-vaccine-barcodes/downloads/Drug-Supply-Chain-Security-Act-508.pdf
- 28. Naughton BD. Medicine Authentication Technology: A Quantitative Study of Incorrect Quarantine, Average Response Times and Offline Issues in a Hospital Setting. BMJ. 2019;9:e026619.10.1136/bmjopen-2018-026619
- 29. Gutorova N, Zhytnyi O, Soloviov O. Falsification of Medical Products: Criminal Law Mechanism Combating Threats to Public Health. Wiad Lek. 2019;72:856-861.10.36740/WLek201905124
- 30. Greenberg MA. Serialisation: Benefits Beyond Regulatory Compliance. Ther Innov Regul Sci. 2014;48:22-27.10.1177/2168479014553034
- 31. Lizano-Díez I, Figueiredo-Escribá C, Piñero-López MÁ, Lastra CF, Mariño EL, Modamio P. Prevention strategies to identify LASA errors: building and sustaining a culture of patient safety. BMC Health Services Research. 2020;20:63.10.1186/s12913-020-4922-3
- 32. European Medicine Agency. Sistemul European de reglementare pentru medicamente. https://www.ema.europa.eu/en/documents/leaflet/european-regulatory-system-medicines-european-medicines-agency-consistent-approach-medicines_ro.pdf
- 33. European Medicine Agency. Pharmacovigilance Risk Assessment Committee (PRAC):Work Plan 2019 https://www.ema.europa.eu/en/documents/work-programme/pharmacovigilance-risk-assessment-committee-prac-work-plan-2019_en.pdf
- 34. Horalek J, Sobeslav V. Track & Trace System with Serialization Prototyping Methodology for Pharmaceutical Industry in EU, in Younas M, Awan I, Holubova I, (eds): Mobile Web and Intelligent Information Systems. Springer International Publishing AG, Cham Switzerland, 2017, 177-186.10.1007/978-3-319-65515-4_15
- 35. GOVINFO. Public Law 113 - 54 - Drug Quality and Security Act. https://www.govinfo.gov/app/details/PLAW-113publ54
- 36. U.S. Food&Drug Administration. Drug Supply Chain Security Act Law and Policies. https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/drug-supply-chain-security-act-law-and-policies
- 37. U.S. Food&Drug Administration. Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance Policy Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-identifier-requirements-under-drug-supply-chain-security-act-compliance-policy-guidance
- 38. Fayzrakhmanov NF. Fighting Trafficking of Falsified and Substandard Medicinal Products in Russia. Int J Risk Saf Med. 2015;27:37-40.10.3233/JRS-150681
- 39. European Union Law. Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products. http://data.europa.eu/eli/dir/2011/62/oj
- 40. European Medicines Verification Organisation. https://emvo-medicines.eu/
- 41. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Overview of ICH. https://admin.ich.org/sites/default/files/2019-11/OverviewOfICH_2019_1128_0.pdf
- 42. World Health Organization. WHO Global Surveillance and Monitoring System for substandard and falsified medical products, Reports and Executive summary. https://www.who.int/medicines/regulation/ssffc/publications/gsms-report-sf/en/
- 43. European Medicine Agency. Buying medicines online https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/falsified-medicines/buying-medicines-online
- 44. Official Journal of the European Union. Commission Implementing (EU) No 699/2014. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:JOL_2014_184_R_0004&from=EN
- 45. Fight the Fakes. Partners. http://fightthefakes.com/partners/
- 46. Newton PN, McGready R, Fernandez F, et al. Manslaughter by fake artesunate in Asia-will Africa be next?. PLOS Medicine. 2006;3:e324.10.1371/journal.pmed.0030324
- 47. Laserson KF, Kenyon AS, Kenyon TA, Layloff T, Binkin NJ. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis. 2001;5:448-454.
- 48. Taylor RB, Shakoor O, Behrens RH, et al. Pharmacopeial qualitz of drugs supplied by Nigerian pharmacies. Lancet. 2001;357:1933-1936.10.1016/S0140-6736(00)05065-0
- 49. Government of Canada. Recalls and safety alerts. A small number of bottles of the antibiotic Rofact (rifampicin) may contain a different drug. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2009/13384a-eng.php
- 50. Government of Canada. Recalls and safety alerts. Immediate recall by Mylan Pharmaceuticals: potential serious risk due to mislabeling of products. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/13584a-eng.php
- 51. L’Agence nationale de sécurité du médicament et des produits de santé. Historique d’une alerte résolue: Furosémide Teva 40 mg, comprimé sécable. https://www.ansm.sante.fr/Dossiers/Furosemide-Teva-40-mg-comprime-secable/Historique-d-une-alerte-resolue-Furosemide-Teva-40-mg-comprime-secable/(offset)/0
- 52. Mackey TK, Cuomo R, Guerra C, Liang BA. After Counterfeit Avastin®--What Have We Learned and What Can Be Done?. Nat Rev Clin Oncol. 2015;12:302-308.10.1038/nrclinonc.2015.3525734637
- 53. Petersen A, Held N, Heide L, Difäm-EPN Minilab Survey Group. Surveillance for Falsified and Substandard Medicines in Africa and Asia by Local Organisations Using the Low-Cost GPHF Minilab. PloS One. 2017;12: e0184165.10.1371/journal.pone.0184165558728428877208
- 54. Attaran A, Barry D, Basheer S, et al. How to achieve international action on falsified and substandard medicine. BMJ. 2012;345:e7381.10.1136/bmj.e738123149211
- 55. Kainer MA, Reagan DR, Nguyen DB, et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med. 2012;367:2194-2203.10.1056/NEJMoa1212972466956223131029
- 56. Twagirumukiza M, Cosijns A, Pringels E, Remon JP, Vervaet C, Van Bortel L. Influence of tropical climate conditions on the quality of antihypertensive drugs from Rwandan pharmacies. Am J Trop Med Hyg. 2009;81:776-781.10.4269/ajtmh.2009.09-010919861610
- 57. Angeli DG, Trezza C. Quality and stability of ramipril generics/copies versus reference ramipril (Tritace): a 3 month stability comparative study. Clin Drug Investig. 2009; 29:667-676.10.2165/11315270-000000000-0000019715383
- 58. Taylor PW, Keenan MHJ. Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane. Curr Med Res Opin. 2008;24:2019-2033.
- 59. U.S. Food&Drug Administration. Recalls, Market withdrawals,& Safety Alerts https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts